Soligenix announces positive preclinical data with multiple heat stable filovirus vaccine candidates

Princeton, n.j., aug. 18, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive data demonstrating the efficacy of multiple filovirus vaccine candidates in nhps, including thermostabilized multivalent vaccines in a single vial platform presentation.
SNGX Ratings Summary
SNGX Quant Ranking